Back to News
Market Impact: 0.3
GSK Wins Japan Approval For Ready-to-Use Shingrix Prefilled Syringe
Source: Nasdaq
Healthcare & BiotechProduct Launches
Japan's Ministry of Health, Labour and Welfare approved GSK's prefilled-syringe presentation of Shingrix, its recombinant zoster vaccine for shingles prevention. The approval expands the product's formulation availability in Japan and could support vaccination convenience and commercial uptake.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
GSK0.65
More News
- Can Specialty Meds Offset GSK's $2.2B Legal Charges and Sizzling R&D Setbacks on Oct. 28?
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- J&J prostate cancer drug shows promising tumor responses in early trial
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
- Fact vs. fiction: Doctors share whether peptides are safe and effective